BREAKING
Helmerich & Payne Jumps 5.3% After Morgan Stanley Maintains Underweight 11 hours ago TransDigm Group Drops 5.8% Amid Sector-Wide Selling 12 hours ago Why Pegasystems Is Dropping 6.0%: DA Davidson Maintains Buy 13 hours ago United Community Banks Delivers 12% Revenue Growth in Q1 2026 13 hours ago Why Fmc Is Dropping 6.8%: Wells Fargo Maintains Equal-Weight 13 hours ago Alpha Metallurgical Resources Jumps 5.9% Amid Sector-Wide Rally 13 hours ago Why Tractor Supply Is Dropping 11%: Baird Maintains Outperform 14 hours ago Brinker International Drops 8.2% After TD Cowen Maintains Buy 14 hours ago Why Calix Is Dropping 3.2%: JP Morgan Maintains Overweight 14 hours ago NetApp Jumps 5.5% Amid Sector-Wide Rally 14 hours ago Helmerich & Payne Jumps 5.3% After Morgan Stanley Maintains Underweight 11 hours ago TransDigm Group Drops 5.8% Amid Sector-Wide Selling 12 hours ago Why Pegasystems Is Dropping 6.0%: DA Davidson Maintains Buy 13 hours ago United Community Banks Delivers 12% Revenue Growth in Q1 2026 13 hours ago Why Fmc Is Dropping 6.8%: Wells Fargo Maintains Equal-Weight 13 hours ago Alpha Metallurgical Resources Jumps 5.9% Amid Sector-Wide Rally 13 hours ago Why Tractor Supply Is Dropping 11%: Baird Maintains Outperform 14 hours ago Brinker International Drops 8.2% After TD Cowen Maintains Buy 14 hours ago Why Calix Is Dropping 3.2%: JP Morgan Maintains Overweight 14 hours ago NetApp Jumps 5.5% Amid Sector-Wide Rally 14 hours ago
ADVERTISEMENT
Breaking News

Synergy CHC Corp. (SNYR) Misses Q4 EPS Estimates

Synergy CHC Corp.

April 1, 2026 1 min read

Synergy CHC Corp.

SNYRSNYR|EPS -$1.35 vs $0.01 est |Rev $6.1M|Net Loss $14.8M

Synergy CHC Corp. posted a net loss of $14.8M for Q4 2025, translating to a loss per share of $1.35 compared to the consensus estimate of $0.01 earnings. The healthcare company’s quarterly results marked a sharp reversal from Q4 2024, when it recorded EPS of $0.01.

Revenue totaled $6.1M for the quarter, down 40.8% from the $10.3M recorded in Q4 2024. The steep decline in both top and bottom line metrics signals significant headwinds for the company during the final three months of the year. Loss per share widened dramatically, down 13400.0% from the prior-year period.

Despite the challenging quarter, Wall Street maintains a relatively optimistic stance on Synergy CHC Corp., with analyst consensus standing at 5 buy, 1 hold, and 0 sell ratings. The quarter’s results represent a substantial setback for the company as it navigates operational challenges in the healthcare sector.

A detailed analysis of Synergy CHC Corp.’s quarter follows shortly on AlphaStreet.

This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.

ADVERTISEMENT